Article info
Original research
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial
- Correspondence to Professor Gordon C Jayson, Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK; gordonjayson{at}nhs.net
Citation
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial
Publication history
- Received February 29, 2024
- Accepted April 25, 2024
- First published May 9, 2024.
Online issue publication
July 01, 2024
Article Versions
- Previous version (9 May 2024).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.